A Multicenter, International, Prospective, Randomized, Vehicle Controlled, Assessor Blinded Study Performed in Subjects With Hard to Heal Wounds, to Evaluate the Efficacy and Safety of Enzymatic Debridement With EscharEx

Trial Profile

A Multicenter, International, Prospective, Randomized, Vehicle Controlled, Assessor Blinded Study Performed in Subjects With Hard to Heal Wounds, to Evaluate the Efficacy and Safety of Enzymatic Debridement With EscharEx

Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs EscharEx (Primary)
  • Indications Leg ulcer; Wounds
  • Focus Therapeutic Use
  • Sponsors MediWound
  • Most Recent Events

    • 03 Aug 2017 According to a MediWound media release, the company has completed enrollment of 38 patients into the second cohort of this trial and expects to report topline results in early September.
    • 21 Feb 2017 According to a MediWound media release, company has progressed for a second cohort of patients in this study and plan to report top-line data from this cohort around mid-2017.
    • 31 Jan 2017 Final positive results were published in the MediWound Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top